Nathan Wong/LinkedIn
Feb 1, 2026, 11:24
Nathan Wong on Economic Benefits of Inclisiran for LDL-C Control
Nathan Wong, Professor and Director, Heart Disease Prevention Program, Division of Cardiology, UC Irvine, shared on LinkedIn:
”Our latest paper in JACC Journals projects approximately 20 million US adults with inadequately controlled LDL-C on statins could benefit from inclisiran treatment, preventing more than 1.6 million ASCVD events over 10 years.”
Read the full article here.
Article: Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
Authors: Nathan Wong, Hridhay Karthikeyan, Wenjun Fan, Batul Electricwala
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 17, 2026, 18:11Ossama Mansour: Landmark MENA Guidelines for Acute Ischemic Stroke Management
-
Mar 17, 2026, 17:48Andrea Van Beek: Improving DOAC Adherence Saves Lives
-
Mar 17, 2026, 17:43Soumen Bhattacharyya: Microangiopathic Hemolytic Anemia Is Often a Hematologic Clue to Underlying Malignancy
-
Mar 17, 2026, 17:37Peter Bou Dib: New Insights on Factor VIII and the Musculoskeletal System
-
Mar 17, 2026, 17:31Armghan Ans: The 2026 Stroke Guidelines Are Excellent, Now the Hard Part
-
Mar 17, 2026, 17:26Danny Hsu: Navigating a Rebalanced Hemostatic State in Decompensated Cirrhosis
-
Mar 17, 2026, 17:21Matías J Alet on Acute Ischemic Stroke With Low NIHSS at NeuroQuality
-
Mar 17, 2026, 17:16S1PR4 Controls Platelet Fibrinogen Binding and Thrombus Formation – JTH
-
Mar 17, 2026, 15:55Mostafa Faisal Mohammed Saleh: Evidence-Based Recommendations for Hodgkin Lymphoma Management in LMICs